Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
MeiraGTx shares offer 'great entry point,' says Piper Sandler » 05:06
07/24/20
07/24
05:06
07/24/20
05:06
MGTX

MeiraGTx

$13.41 /

-1.09 (-7.52%)

Piper Sandler analyst…

Piper Sandler analyst Tyler Van Buren believes current MeiraGTx share levels offer a "great entry point" for investors. Through year-end, investors should expect to receive more XLRP data, which "should continue to be positive," Van Buren tells investors in a research note. By year-end, the analyst also expects initial Phase I/II data from the first few radiation-induced xerostomia patients who were treated before the pandemic. MeiraGTx's six clinical-stage gene therapy programs are receiving "little-to-no value" when considering the existing cash and manufacturing plant, says Van Buren.

ShowHide Related Items >><<
MGTX MeiraGTx
$13.41 /

-1.09 (-7.52%)

MGTX MeiraGTx
$13.41 /

-1.09 (-7.52%)

07/17/20 H.C. Wainwright
H.C. Wainwright says Applied Genetic still in 'pole position' in XLRP
07/17/20 Piper Sandler
MeiraGTx should be bought after XLRP data, says Piper Sandler
12/16/19 Piper Sandler
MeiraGTx has most exciting Parkinson's disease program, says Piper Jaffray
09/03/19 Piper Sandler
MeiraGTx initiated with an Overweight at Piper Jaffray
MGTX MeiraGTx
$13.41 /

-1.09 (-7.52%)

  • 08
    Aug
Recommendations
H.C. Wainwright says Applied Genetic still in 'pole position' in XLRP » 12:16
07/17/20
07/17
12:16
07/17/20
12:16
AGTC

Applied Genetic

$5.90 /

+0.33 (+5.92%)

, MGTX

MeiraGTx

$14.30 /

+2.2 (+18.18%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Joseph Pantginis reiterates his Buy rating on shares of Applied Genetic Technologies (AGTC) after competitor MeiraGTX (MGTX) announced interim safety and efficacy data from the ongoing Phase 1/2 clinical trial of AAV-RPGR for the treatment of X-linked retinitis pigmentosa, or XLRP. Although he calls the six-month data reported by MeiraGTX "overall positive," Pantginis believes they fall behind those announced by Applied "on multiple levels," he tells investors. The analyst, who continues to view AGTC-501's profile as "highly competitive," keeps an $18 price target on the shares.

ShowHide Related Items >><<
MGTX MeiraGTx
$14.30 /

+2.2 (+18.18%)

AGTC Applied Genetic
$5.90 /

+0.33 (+5.92%)

AGTC Applied Genetic
$5.90 /

+0.33 (+5.92%)

07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
06/23/20
Fly Intel: Top five analyst initiations
06/23/20 Cantor Fitzgerald
Applied Genetic initiated with an Overweight at Cantor Fitzgerald
06/22/20 Cantor Fitzgerald
Applied Genetic initiated with an Overweight at Cantor Fitzgerald
MGTX MeiraGTx
$14.30 /

+2.2 (+18.18%)

07/17/20 Piper Sandler
MeiraGTx should be bought after XLRP data, says Piper Sandler
12/16/19 Piper Sandler
MeiraGTx has most exciting Parkinson's disease program, says Piper Jaffray
09/03/19 Piper Sandler
MeiraGTx initiated with an Overweight at Piper Jaffray
MGTX MeiraGTx
$14.30 /

+2.2 (+18.18%)

AGTC Applied Genetic
$5.90 /

+0.33 (+5.92%)

  • 07
    Feb
  • 08
    Aug
Recommendations
MeiraGTx should be bought after XLRP data, says Piper Sandler » 11:27
07/17/20
07/17
11:27
07/17/20
11:27
MGTX

MeiraGTx

$12.75 /

+0.65 (+5.37%)

, BIIB

Biogen

$283.00 /

+3.33 (+1.19%)

Piper Sandler analyst…

Piper Sandler analyst Tyler Van Buren reiterates an Overweight rating on MeiraGTx (MGTX) with a $40 price target after the company presented six-month data from the ongoing Phase 1/2 clinical trial of AAV-RPGR, an investigational gene therapy in development for the treatment of patients with X-linked retinitis pigmentosa. This is the most comprehensive XLRP data presentation to date, Van Buren tells investors in a research note. The retinal sensitivity improvements appear at least as good as competitors AGTC and Biogen/Nightstar (BIIB), contends the analyst. He expects MeiraGTx's program to advance into Phase III soon and believes XLRP could be a $1.5B global opportunity. Van Buren says buy shares of MeiraGTx at current levels.

ShowHide Related Items >><<
MGTX MeiraGTx
$12.75 /

+0.65 (+5.37%)

BIIB Biogen
$283.00 /

+3.33 (+1.19%)

MGTX MeiraGTx
$12.75 /

+0.65 (+5.37%)

12/16/19 Piper Sandler
MeiraGTx has most exciting Parkinson's disease program, says Piper Jaffray
09/03/19 Piper Sandler
MeiraGTx initiated with an Overweight at Piper Jaffray
BIIB Biogen
$283.00 /

+3.33 (+1.19%)

07/13/20 Goldman Sachs
Biogen price target lowered to $257 from $300 at Goldman Sachs
07/08/20 Credit Suisse
Biogen submits Aducanumab BLA, upside possible near-term, says Credit Suisse
07/08/20 Stifel
Biogen submission of Aducanumab BLA 'an incremental positive,' says Stifel
07/08/20 Goldman Sachs
Goldman says Biogen BLA submission for Alzheimer's drug an incremental positive
MGTX MeiraGTx
$12.75 /

+0.65 (+5.37%)

BIIB Biogen
$283.00 /

+3.33 (+1.19%)

  • 08
    Aug
BIIB Biogen
$283.00 /

+3.33 (+1.19%)

BIIB Biogen
$283.00 /

+3.33 (+1.19%)

BIIB Biogen
$283.00 /

+3.33 (+1.19%)

Hot Stocks
MeiraGTx announces clinical data from Phase 1/2 trial of AAV-RPGR » 07:34
07/17/20
07/17
07:34
07/17/20
07:34
MGTX

MeiraGTx

$12.10 /

-0.54 (-4.27%)

, JNJ

Johnson & Johnson

$149.18 /

+0.86 (+0.58%)

MeiraGTx Holdings (MGTX)…

MeiraGTx Holdings (MGTX) announced six-month data from the ongoing Phase 1/2 clinical trial of AAV-RPGR, an investigational gene therapy in development for the treatment of patients with X-linked retinitis pigmentosa with genetically confirmed variants in the RPGR gene. Significant improvement in vision was demonstrated in the dose escalation phase of the trial and AAV-RPGR was found to be generally well tolerated. These initial results from the trial are being presented as a late-breaker oral presentation at the American Society of Retina Specialists 2020 Virtual Annual Meeting. MeiraGTx and Janssen Pharmaceuticals (JNJ) are jointly developing AAV-RPGR as part of a broader collaboration to develop and commercialize gene therapies for the treatment of inherited retinal diseases. The ongoing Phase 1/2 MGT009 clinical trial consists of three phases: dose-escalation, dose-confirmation, and dose-expansion. In the dose-escalation phase, adults were administered low, intermediate, or high dose AAV-RPGR. Each patient was treated with subretinal delivery of AAV-RPGR in the eye that was more affected at baseline. The patient's other eye served as an untreated control. The primary endpoint of the trial is safety, with secondary endpoints assessing changes in visual function at pre-specified timepoints post-treatment. Baseline values were determined in triplicate. At six months, significant improvement in retinal sensitivity was demonstrated in patients treated with low and intermediate dose AAV-RPGR. Improvement was evident at first post-treatment perimetry assessments at three months, with improvements generally sustained or increased at six months. Significant differences were observed in retinal sensitivity between treated and untreated eyes over time. Based on the robust safety and efficacy signals observed in the dose escalation portion of the study, the low and intermediate doses were selected for use in the ongoing randomized, controlled dose-expansion phase of the trial. Based on the safety and efficacy data demonstrated in the MGT009 trial to date, MeiraGTx and Janssen expect to advance AAV-RPGR into the Phase 3 Lumeos clinical trial for the treatment of patients with XLRP caused by mutations in RPGR gene. Data obtained to date suggest AAV-RPGR is generally well-tolerated. Most adverse events were related to the surgical delivery procedure, were transient and resolved without intervention. There were no dose-limiting events. Inflammatory responses to therapy were observed in two out of three patients in the high dose cohort, which may have been associated with decreased activity of AAV-RPGR in these patients. Inflammation was effectively managed with an extended steroid protocol. Six-month data from the dose escalation portion of the study demonstrated meaningful improvement from baseline in retinal sensitivity in the low and intermediate dose cohorts. Importantly, these improvements were evident when assessed with two perimetry approaches and three analysis metrics. Significant differences in mean retinal sensitivity were observed between treated eyes and untreated eyes in the intermediate dose cohort: 1.02 dB. Significant differences were observed in central visual field progression ratebetween treated eyes and untreated eyes in both the low, 1.10 dB-sr/year and intermediate, 1.26 dB-sr/year, dose cohorts. Efficacy signals were observed at first post-treatment assessments at three months, with improvements generally sustained or increased at six months. Perimetry is a sensitive standard-of-care measure of retinal function that reproducibly determines retinal sensitivity both cross-sectionally and longitudinally, thereby accurately defining disease progression over time.

ShowHide Related Items >><<
MGTX MeiraGTx
$12.10 /

-0.54 (-4.27%)

JNJ Johnson & Johnson
$149.18 /

+0.86 (+0.58%)

MGTX MeiraGTx
$12.10 /

-0.54 (-4.27%)

12/16/19 Piper Sandler
MeiraGTx has most exciting Parkinson's disease program, says Piper Jaffray
09/03/19 Piper Sandler
MeiraGTx initiated with an Overweight at Piper Jaffray
JNJ Johnson & Johnson
$149.18 /

+0.86 (+0.58%)

07/17/20 Goldman Sachs
J&J valuation discount to S&P 500 'too wide,' says Goldman Sachs
07/17/20 Citi
Johnson & Johnson price target raised to $170 from $165 at Citi
07/16/20 Goldman Sachs
J&J delay to robotic surgery program a positive for Intuitive, says Goldman
07/13/20 Oppenheimer
Relmada Therapeutics initiated with an Outperform at Oppenheimer
MGTX MeiraGTx
$12.10 /

-0.54 (-4.27%)

JNJ Johnson & Johnson
$149.18 /

+0.86 (+0.58%)

  • 08
    Aug
JNJ Johnson & Johnson
$149.18 /

+0.86 (+0.58%)

JNJ Johnson & Johnson
$149.18 /

+0.86 (+0.58%)

JNJ Johnson & Johnson
$149.18 /

+0.86 (+0.58%)

Over a month ago
Earnings
MeiraGTx reports Q1 EPS (43c), consensus (48c) » 17:18
05/07/20
05/07
17:18
05/07/20
17:18
MGTX

MeiraGTx

$14.25 /

+0.8 (+5.95%)

Cash, cash equivalents…

Cash, cash equivalents and restricted cash were $210.8 million as of March 31, 2020, compared to $227.4 million as of March 31, 2019.License revenue was $4.2 million for the quarter ended March 31, 2020, compared to $0.8 million for the quarter ended March 31, 2019. The increase represents increased amortization of the $100.0 million upfront payment that the Company received in March 2019 from its collaboration agreement with Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

ShowHide Related Items >><<
MGTX MeiraGTx
$14.25 /

+0.8 (+5.95%)

12/16/19 Piper Sandler
MeiraGTx has most exciting Parkinson's disease program, says Piper Jaffray
09/03/19 Piper Sandler
MeiraGTx initiated with an Overweight at Piper Jaffray
05/15/19 Barclays
MeiraGTx price target raised to $30 from $20 at Barclays
Over a quarter ago
Hot Stocks
MeiraGTx Holdings trading resumes  09:51
03/20/20
03/20
09:51
03/20/20
09:51
MGTX

MeiraGTx

$11.68 /

+1.06 (+9.98%)

 
ShowHide Related Items >><<
MGTX MeiraGTx
$11.68 /

+1.06 (+9.98%)

12/16/19 Piper Sandler
MeiraGTx has most exciting Parkinson's disease program, says Piper Jaffray
09/03/19 Piper Sandler
MeiraGTx initiated with an Overweight at Piper Jaffray
05/15/19 Barclays
MeiraGTx price target raised to $30 from $20 at Barclays
Hot Stocks
MeiraGTx Holdings trading halted, volatility trading pause  09:41
03/20/20
03/20
09:41
03/20/20
09:41
MGTX

MeiraGTx

$10.62 /

+ (+0.00%)

 
ShowHide Related Items >><<
MGTX MeiraGTx
$10.62 /

+ (+0.00%)

12/16/19 Piper Sandler
MeiraGTx has most exciting Parkinson's disease program, says Piper Jaffray
09/03/19 Piper Sandler
MeiraGTx initiated with an Overweight at Piper Jaffray
05/15/19 Barclays
MeiraGTx price target raised to $30 from $20 at Barclays
Hot Stocks
MeiraGTx announces PRIME, ATMP designations for AAV-RPGR gene therapy » 09:03
03/02/20
03/02
09:03
03/02/20
09:03
MGTX

MeiraGTx

$16.25 /

+0.45 (+2.85%)

MeiraGTx Holdings…

MeiraGTx Holdings announced that the European Medicines Agency has granted Priority Medicines and Advanced Therapy Medicinal Product designations to AAV-RPGR, MeiraGTx's investigational gene therapy for the treatment of x-linked retinitis pigmentosa caused by mutations in the RPGR gene. PRIME designation was granted based on clinical data from MeiraGTx and Janssen's ongoing Phase 1/2 trial of AAV-RPGR in patients with XLRP. AAV-RPGR is the only gene therapy in development for the treatment of XLRP to receive PRIME designation.

ShowHide Related Items >><<
MGTX MeiraGTx
$16.25 /

+0.45 (+2.85%)

12/16/19 Piper Sandler
MeiraGTx has most exciting Parkinson's disease program, says Piper Jaffray
09/03/19 Piper Sandler
MeiraGTx initiated with an Overweight at Piper Jaffray
05/15/19 Barclays
MeiraGTx price target raised to $30 from $20 at Barclays
Recommendations
MeiraGTx has most exciting Parkinson's disease program, says Piper Jaffray » 05:24
12/16/19
12/16
05:24
12/16/19
05:24
MGTX

MeiraGTx

$20.95 /

+0.5 (+2.45%)

Piper Jaffray analyst…

Piper Jaffray analyst Tyler Van Buren says MeiraGTx has the most exciting Parkinson's disease development program that he's seen. The company's AAV-GAD is the only gene therapy to have generated statistically significant results via the gold standard UPDRS, Van Buren tells investors in a research note. He believes AAV-GAD has multi-billion dollar potential given the ~300,000 addressable patients in the U.S. alone. Van Buren reiterates an Overweight rating on MeiraGTx with a $40 price target.

ShowHide Related Items >><<
MGTX MeiraGTx
$20.95 /

+0.5 (+2.45%)

09/03/19 Piper Sandler
MeiraGTx initiated with an Overweight at Piper Jaffray
05/15/19 Barclays
MeiraGTx price target raised to $30 from $20 at Barclays
02/27/19 Chardan
MeiraGTx price target raised to $40 from $30 at Chardan
Conference/Events
MeiraGTx management to meet with Piper Jaffray » 04:55
11/26/19
11/26
04:55
11/26/19
04:55
MGTX

MeiraGTx

$17.46 /

-0.33 (-1.86%)

Meetings to be held in…

Meetings to be held in London, England on November 25 and in Stockholm, Sweden on November 26 hosted by Piper Jaffray.

ShowHide Related Items >><<
MGTX MeiraGTx
$17.46 /

-0.33 (-1.86%)

09/03/19 Piper Sandler
MeiraGTx initiated with an Overweight at Piper Jaffray
05/15/19 Barclays
MeiraGTx price target raised to $30 from $20 at Barclays
02/27/19 Chardan
MeiraGTx price target raised to $40 from $30 at Chardan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.